Back

SH2D2A is an indicator of favourable prognosis in bladder cancer and is enriched in Treg cells

Gilmour, B. C.; Visser, J. G.; Kohn-Luque, A.; Lossius, A.; Borowicz, P.; Spurkland, A.

2025-01-17 bioinformatics
10.1101/2025.01.13.632739 bioRxiv
Show abstract

Given the expanding availability of RNA-seq and other such high dimensional data it is now possible to consider a complementary approach working in the opposite direction i.e., from transcriptomics up towards protein function. This approach may prove fruitful in producing information on the function of cytosolic-bound proteins such as adapter proteins. To test the validity of this method, we made use of several public datasets to interrogate the cancer-specific role of the adapter protein SH2D2A: a protein enriched in T and NK cells and a known interactor of the kinase LCK, whose function remains uncertain. We found that SH2D2A is a favourable marker for prognosis in urothelial bladder cancer (BLCA). Digging further, we identified a population of SH2D2A+ FOXP3+ IL2RAhi activated Tregs as the main expressors of SH2D2A in BLCA. This suggests that the expression of SH2D2A in these Tregs contributes to a beneficial prognostic effect. Further comprehension of SH2D2As function in these cells holds the potential for advancing treatment in BLCA and diversifying possible targets for immunotherapies.

Matching journals

The top 7 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.